论文部分内容阅读
目的 建立小鼠肝脏种植性肝癌模型，评价添加新型佐剂的全细胞肿瘤瘤苗的治疗效果，包括免疫学参数及小鼠存活期，探讨该肿瘤瘤苗的作用机制。方法Ｂａｌｂ／ｃ小鼠肝脏成功接种肿瘤后，分成４组，各组行不同的治疗。第１组单纯切除肿瘤，不做免疫治疗；第Ⅱ组切除肿瘤，用新型细胞瘤苗进行免疫治疗；第Ⅲ组不切除肿瘤，用新型瘤苗进行免疫治疗；第Ⅳ组为对照组，只进行开腹、关腹。第２８天处死各组半数小鼠，取血检测血清中ＩＬ－１０和ＩＦＮ－γ的水平；取脾用ＦＡＣＳ检测ＣＤ４／ＣＤ8 和 ＩＦＮ－γ／ＩＬ－１０双阳性细胞的比例。各组所余小鼠继续饲养，鹏存活期。结果第腴血清ＩＦＮ-γ的水平较其余组明显升高（ｐ＜０.０１）；血清 ＩＬ－１０的水平较其他组明显降低（ｐ＜０．０１）；ＣＤ８＋／ＩＦＮ－γ+细胞的比例明显高于其他各组（ｐ＜０.０１）； ＣＤ８+／ＩＬ－１０+细胞的比例明显低于其他各组（ｐ＜０.０１）；ＣＤ４＋／ＩＦＮ-γ+细胞的比例明显高于靴各组（ｐ＜０.０１）；ＣＤ４＋／ＩＬ－１０＋细胞的比例明显低于其他各组（ｐ＜０.０１）．同时，第Ⅱ组荷瘤小鼠的生存期亦有明显延长。各组肺或淋巴结转移无统计学意义。结论新型同系肿瘤细胞瘤苗可激发特异性细胞介导的免疫
OBJECTIVE: To establish a mouse model of hepatocellular carcinoma (HCC) in mice and evaluate the therapeutic effect of the adjuvant-added whole-cell tumor vaccine, including immunological parameters and survival of mice. Methods Balb / c mice were successfully inoculated into the liver and divided into 4 groups. Each group received different treatments. The first group of simple resection of the tumor, not immunotherapy; Group II excision of the tumor, with new cell vaccine for immunotherapy; Group III tumor excision, immunotherapy with a new vaccine; Group IV for the control group, only Open an abdomen, close the abdomen. On the 28th day, half of mice in each group were sacrificed and the levels of IL-10 and IFN-γ in serum were determined by blood sampling. The ratio of CD4 / CD8 and IFN-γ / IL-10 double positive cells was determined by FACS. The remaining mice in each group continue to raise, Peng survival period. Results Serum levels of IFN-γ were significantly higher than those of the other groups (p <0.01), serum IL-10 levels were significantly lower than those of the other groups (p <0.01), while CD8 + / IFN- The proportion of CD8 + / IL-10 + cells was significantly lower than other groups (p <0.01); the proportion of CD4 + / IFN- γ + cells was significantly higher than that of other groups The percentage of CD4 + / IL-10 + cells was significantly lower in boots than in other groups (p <0.01). At the same time, group II tumor-bearing mice also significantly prolonged survival. The lung or lymph node metastasis in each group was not statistically significant. Conclusions The novel syngeneic tumor cell vaccine can stimulate specific cell-mediated immunity